COVID-19 Vaccination Damage Compensation, Ulsan Was Proactive

Ulsan City Receives 2,439 Vaccine Adverse Reaction Reports

2,305 Cases Reviewed, 885 Compensation Decisions Made

Compensation Approval Rate Higher Than National Average

Ulsan has been found to be more proactive in compensating for adverse reactions reported after COVID-19 vaccinations compared to other cities and provinces.


Since April 2021, Ulsan City has received a total of 2,439 claims for compensation related to adverse reactions following COVID-19 vaccinations as of April 21.


Out of these, reviews have been completed for 2,305 cases (94.5%), and compensation has been finalized for 885 cases (38.4%), including one death.


The compensation approval rate for COVID-19 vaccination adverse reactions in Ulsan City (38.4%) was 13.2 percentage points higher than the national average (25.2%).


Additionally, to expedite the review process, since January 25 of last year, Ulsan City has independently reviewed 1,499 applications for small medical expenses under 300,000 KRW, which were transferred from the central government to the city and province level, and compensated 105 cases.


Furthermore, 28 individuals who are eligible for medical expense support for 14 suspected related diseases with insufficient causality to vaccination, in addition to 12 types of adverse reactions recognized as causally related, are currently being processed individually. Compensation has also been completed for two individuals eligible for consolation payments due to undetermined cause of death after autopsy.


An official from Ulsan City stated, “The compensation claims for adverse reactions after vaccination apply not only to COVID-19 but also to 22 types of national immunizations. We encourage individuals to apply through medical institutions or local health centers if they experience adverse reactions after vaccination.”

COVID-19 Vaccination. [Image source=Yonhap News]

COVID-19 Vaccination. [Image source=Yonhap News]

원본보기 아이콘

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.